Broadfin Capital’s Neurogene NGNE Stock Holding History

Broadfin Capital’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-26,588	Closed	-$3.69M	–	95
2015 Q2	$3.69M	Hold	26,588	–	–	0.2%	81
2015 Q1	$4.37M	Hold	26,588	–	–	0.34%	69
2014 Q4	$3.99M	Buy	26,588 +1,063	+4%	+$151K	0.35%	57
2014 Q3	$3.4M	Hold	25,525	–	–	0.36%	60
2014 Q2	$4.81M	Hold	25,525	–	–	0.47%	52
2014 Q1	$6.5M	Buy	+25,525	New	+$6.56M	0.63%	43

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Broadfin Capital's NGNE Position: Q3 2015 in Review

Broadfin Capital sold out of Neurogene (NGNE) in Q3 2015, closing a stake of 26,588 shares — an estimated $3.69M sold.

Broadfin Capital first reported a position in NGNE in Q1 2014 and held it in 6 quarters. The position peaked at $6.5M in Q1 2014. 33 funds tracked by Wall St. Rank hold NGNE as of Q3 2015.

Broadfin Capital reported no remaining Neurogene position as of Q3 2015 after selling out during the quarter.
Broadfin Capital sold 26,588 Neurogene shares in Q3 2015, an estimated $3.69M.
Broadfin Capital first reported a position in Neurogene in Q1 2014 and held it in 6 quarters.
Broadfin Capital's Neurogene position peaked at $6.5M in Q1 2014.
33 funds tracked by Wall St. Rank held Neurogene as of Q3 2015.

Based on Broadfin Capital's 13F filing for Q3 2015, filed 16 Nov 2015.